Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome

Ropper, 1986, Unusual clinical variants and signs in Guillain-Barré syndrome, Arch Neurol, 43, 1150, 10.1001/archneur.1986.00520110044012

Nagashima, 2007, Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome, Arch Neurol, 64, 1519, 10.1001/archneur.64.10.1519

Ropper, 1994, Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness, Arch Neurol, 51, 671, 10.1001/archneur.1994.00540190051014

Arai, 2003, Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without anti-GT1a IgG antibody, Muscle Nerve, 28, 246, 10.1002/mus.10424

Chan, 2012, Non-demyelinating, reversible conduction failure in a case of pharyngeal-cervical-brachial weakness overlapped by Fisher syndrome, J Neurol Sci, 321, 103, 10.1016/j.jns.2012.07.037

Ropper, 1991, Guillain-Barré Syndrome

Yuki, 2012, Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes, J Neurol, 259, 1181, 10.1007/s00415-011-6330-4

Miura, 2002, Guillain-Barré syndrome presenting pharyngeal-cervical-brachial weakness in the recovery phase, Eur Neurol, 48, 53, 10.1159/000064963

Mizoguchi, 1994, Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome, J Neurol Neurosurg Psychiatry, 57, 1121, 10.1136/jnnp.57.9.1121

Kashihara, 1998, IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome, J Neurol Neurosurg Psychiatry, 65, 799, 10.1136/jnnp.65.5.799

Osaki, 2002, Asymmetric pharyngeal-cervical-brachial weakness associated with anti-GT1a IgG antibody, Acta Neurol Scand, 106, 234, 10.1034/j.1600-0404.2002.01271.x

Okuda, 2002, Fulminant Guillain-Barré syndrome after Campylobacter jejuni enteritis and monospecific anti-GT1a IgG antibody, Intern Med, 41, 889, 10.2169/internalmedicine.41.889

Pan, 2004, Pharyngeal-brachial palsy after cytomegalovirus colitis, Neurology, 62, 153, 10.1212/01.WNL.0000101469.25169.A1

Capasso, 2010, Reversible conduction failure in pharyngeal-cervical-brachial variant of Guillain-Barré syndrome, Muscle Nerve, 42, 608, 10.1002/mus.21801

Ito, 2011, Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum, J Neurol Neurosurg Psychiatry, 82, 294, 10.1136/jnnp.2010.222836

Onodera, 2002, Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis, J Neurol Sci, 205, 83, 10.1016/S0022-510X(02)00241-1

O'Leary, 1996, Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides, J Neurol Neurosurg Psychiatry, 61, 649, 10.1136/jnnp.61.6.649

Numata, 2011, Case of a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without pharyngeal palsy, No To Hattatsu, 43, 482

Ogawara, 2000, Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan, Ann Neurol, 48, 624, 10.1002/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O

Chiba, 1993, Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies, Neurology, 43, 1911, 10.1212/WNL.43.10.1911

Yuki, 1992, Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies, Muscle Nerve, 15, 899, 10.1002/mus.880150806

Koga, 2002, Anti-GT1a IgG in Guillain-Barré syndrome, J Neurol Neurosurg Psychiatry, 72, 767, 10.1136/jnnp.72.6.767

Yowler, 2004, Glycosphingolipids-sweets for botulinum neurotoxin, Glycoconj J, 21, 287, 10.1023/B:GLYC.0000046271.64647.fd

Kitamura, 1980, Interaction between Clostridium botulinum neurotoxin and gangliosides, Biochim Biophys Acta, 628, 328, 10.1016/0304-4165(80)90382-7

Kamata, 1986, Evidence for direct binding of Clostridium botulinum type E derivative toxin and its fragments to gangliosides and free fatty acids, Biochem Biophys Res Commun, 140, 1015, 10.1016/0006-291X(86)90736-9

Kimoto, 2006, Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies, Neurology, 67, 1837, 10.1212/01.wnl.0000244468.22377.6b

Susuki, 2007, Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers, J Neurosci, 27, 3956, 10.1523/JNEUROSCI.4401-06.2007

McGonigal, 2010, Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice, Brain, 133, 1944, 10.1093/brain/awq119

Sejvar, 2011, Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data, Vaccine, 29, 599, 10.1016/j.vaccine.2010.06.003

Nishimoto, 2004, Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination, J Neuroimmunol, 148, 200, 10.1016/j.jneuroim.2003.11.017

Padua, 1999, Neurophysiological assessment in the diagnosis of botulism: usefulness of single-fiber EMG, Muscle Nerve, 22, 1388, 10.1002/(SICI)1097-4598(199910)22:10<1388::AID-MUS8>3.0.CO;2-3

Kuwabara, 2011, Neuromuscular transmission is not impaired in axonal Guillain-Barré syndrome, J Neurol Neurosurg Psychiatry, 82, 1174, 10.1136/jnnp.2010.210708

Kuwabara, 2007, Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle, J Neuroimmunol, 189, 158, 10.1016/j.jneuroim.2007.07.001

Yuki, 2012, Guillain-Barré syndrome, N Engl J Med, 366, 2294, 10.1056/NEJMra1114525